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Abstract 
Background: In France, the Ministry of Health has implemented a comprehensive program for rare diseases (RD) that 
includes an epidemiological program as well as the establishment of expert centers for the clinical care of patients 
with RD. Since 2007, most of these centers have entered the data for patients with developmental disorders into the 
CEMARA population‑based registry, a national online data repository for all rare diseases. Through the CEMARA web 
portal, descriptive demographic data, clinical data, and the chronology of medical follow‑up can be obtained for 
each center. We address the interest and ongoing challenges of this national data collection system 10 years after its 
implementation.
Methods: Since 2007, clinicians and researchers have reported the “minimum dataset (MDS)” for each patient pre‑
senting to their expert center. We retrospectively analyzed administrative data, demographic data, care organization 
and diagnoses.
Results: Over 10 years, 228,243 RD patients (including healthy carriers and family members for whom experts denied 
any suspicion of RD) have visited an expert center. Among them, 167,361 were patients affected by a RD (median 
age 11 years, 54% children, 46% adults, with a balanced sex ratio), and 60,882 were unaffected relatives (median age 
37 years). The majority of patients (87%) were seen no more than once a year, and 52% of visits were for a diagnostic 
procedure. Among the 2,869 recorded rare disorders, 1,907 (66.5%) were recorded in less than 10 patients, 802 (28%) 
in 10 to 100 patients, 149 (5.2%) in 100 to 1,000 patients, and 11 (0.4%) in > 1,000 patients. Overall, 45.6% of individuals 
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Background
Rare diseases (RD) are diseases with a prevalence infe-
rior to one in 2000 in the general population. Though 
rare, they are a major public health concern since they 
are collectively common, and 2–3% of births and 7–8% 
of adults are or will be affected by an RD [1]. More than 
three million French people and about 25 million Euro-
peans are affected by one of the 7,000 currently recog-
nized RD. In half of all cases, RD affect children under 
5  years, and they are responsible for 10% of deaths in 
children aged 1 to 5 years [1]. Eighty percent of RDs are 
of genetic origin. Most often, they are severe chronic 
diseases, and they can also be progressive. They consid-
erably affect the quality of life of affected patients, caus-
ing motor, sensory or intellectual deficits in 50% of cases, 
and total dependency in 9% of cases [1]. There is a crucial 
lack of treatment for RD, since only 5% of these disorders 
have an available treatment [2]. For these reasons, three 
French national plans (Plan National Maladies Rares or 
PNMR) have been successively established for RD since 
2004, enabling France to play a leading role in the field of 
RD in Europe [3]. The first PNMR structured a national 
network of 131 multidisciplinary reference centers for 
RD (RCRD) and more than 500 centers of expertise for 
RD (CERD), which was then revised with the 3rd PNMR, 
resulting in a total of 387 RCRD and 1,800 CERD. The 
RCRD form a network of national excellence centers 
with extensive geographical coverage. The CERD provide 
RCRD expertise to local hospitals. This network gives 
patients the opportunity to access comprehensive clini-
cal work-ups and regular follow-up as close as possible 
to their homes. The interactions between the RCRD and 
expert clinical laboratories, research laboratories, patient 
support groups, and the other various medico-social spe-
cialties in the patient care pathways have been structured 
into 23 thematic networks for RD (each of them encom-
passing RCRD and CERD for one group of diseases, 
accredited by the 2nd PNMR) [4]. Their objectives are to 
optimize the supply of care, improve education and train-
ing, and stimulate the development of research and inno-
vation in the field of RD. The way in which patients with 
RD are managed in France strongly inspired the creation 
of European Reference Networks by the European Com-
mission [5].
The PNMR have focused on improving knowledge 
about the epidemiology of RD through the constitu-
tion of a dedicated registry collecting information from 
the rare disease network. In order to fulfill this objec-
tive, a population-based registry, called CEMARA, was 
launched in 2007. It collects epidemiological information 
about RD and related medical activities from RCRD and 
CERD on a national level. The goal of CEMARA was to 
improve the understanding of the burden of disease for 
rare conditions, to determine the resources needed for 
healthcare and social services, and to identify patients 
eligible for natural history studies and clinical trials [6]. 
A minimum dataset (MDS) [31] has been set up (Addi-
tional file  1: Table  S1). Physicians and paramedical 
workers (psychologists, genetic counsellors, and social 
workers) enter data from the RD centers, and the system 
allows longitudinal follow-up of individual patients. The 
French Data Protection Authority authorized CEMARA 
in 2007. It is compliant with European GDPR regulation. 
A Scientific Committee has validated the studies issued 
from the CEMARA data. The CEMARA project has reg-
istered 500,000 RD patients from 151 RCRD (out of 387), 
412 CERD and recorded over 4000 RD.
Among the 23 accredited health networks, AnDDI-
Rares (Anomalies du Développement avec ou sans Défi-
ciences Intellectuelles de causes Rares) is the network of 
medical genetic services implanted in university hospi-
tals. It focuses on individuals with developmental abnor-
malities (malformations and intellectual disability (ID)) 
or not, and works with more than 5000 distinct rare 
monogenic diseases and a large number of chromosomal 
abnormalities [7]. These diseases have a prevalence of 3% 
(about 1.8 million people and 40,000 new cases per year 
in France). These disorders share common characteris-
tics: (i) an often difficult diagnosis requiring clinical and 
biological expertise, (ii) a high rate of patients with no 
diagnosis, (iii) coordinated care relying often on multi-
disciplinary therapy facilities and special-needs schooling 
had no diagnosis and 6.7% had an uncertain diagnosis. Children were mainly referred by their pediatrician (46%; 
n = 55,755 among the 121,136 total children referrals) and adults by a medical specialist (34%; n = 14,053 among the 
41,564 total adult referrals). Given the geographical coverage of the centers, the median distance from the patient’s 
home was 25.1 km (IQR = 6.3 km‑64.2 km).
Conclusions: CEMARA provides unprecedented support for epidemiological, clinical and therapeutic studies in the 
field of RD. Researchers can benefit from the national scope of CEMARA data, but also focus on specific diseases or 
patient subgroups. While this endeavor has been a major collective effort among French RD experts to gather large‑
scale data into a single database, it provides tremendous potential to improve patient care.
Keywords: Rare disease, Developmental disorders, Data warehouse, Epidemiology
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requiring multiple interactions between hospital and 
non-hospital partners, and (iv) the need for epidemio-
logical, clinical and translational research regarding the 
natural history and pathophysiology of developmental 
abnormalities, with a focus on long-awaited therapeutic 
solutions (often requiring multicenter cohort studies). 
Initially, according to the first PNMR, the AnDDI-Rares 
network included 22 constitutive RCRD grouped under 
the supervision of 8 coordinator RCRD, and 7 CERD. 
Currently, AnDDI-Rares includes 20 constitutive uni-
versity hospitals grouped under the coordination of six 
RCRD (one per large French inter-region), and 29 fur-
ther CERD (Additional file  2: Figure  S1A). Besides the 
facilities for care and treatment, AnDDI-Rares includes 
diagnostic laboratories (38 for molecular genetics, 44 
for cytogenetics, 48 fetal pathology units), 32 research 
teams, and over 60 family support groups. The 26 depart-
ments forming the AnDDI-Rares RCRD (beneficiary of 
an operating grant from the French state) have filled out 
the register since 2007. Participation of the CERD (which 
does not have a grant) was optional.
Here, to gain knowledge about patients with develop-
mental disorders and their care pathway in France, we 
studied the cohort of patients followed up in AnDDI-
Rares network for developmental disorders, using data 
from the first 10 years of CEMARA data collection. We 
then focused on four sub-cohorts of patients diagnosed 
with four different specific diseases to study their char-
acteristics and follow-up. Lastly, we focused on the sub-
cohort of patients with chromosomal anomalies.
Methods
Study design
We performed a cross-sectional cohort study on a pop-
ulation-based cohort. We included all the consultations 
of all patients with developmental abnormalities seen in a 
RCRD or a CERD of the AnDDI-Rares network (Fig. 1A) 
within the 2007–2017 period in France. Tele-expertise or 
expert opinions on medical files were reported in some 
cases and therefore included in the study.
Data collection
An MDS with mandatory and optional information was 
collected for each patient and visit so that all centers had 
a common core data set (Additional file 1: Table S1). The 
following items were mandatory for the MDS: demo-
graphics data (birth and death date, sex, residential 
address) for the index case and family members when 
necessary, diagnosis, type of visit, and objective of the 
activity. An identification module ensured that there 
were no identity doubles using a double-entry prevention 
function [8].
If necessary, several diagnoses were provided for a 
given patient. Optional information included antenatal 
or neonatal data, mode of inheritance, additional key-
words for describing atypical signs and symptoms, or for 
patients presenting with a still unknown diagnosis (Addi-
tional file  1: Table  S1). For the diagnosis labels of the 
patient records, a classification was set up with the health 
professionals corresponding to their needs. The database 
was linked to Orphanet, which has designed specific the-
sauri dedicated to RD. A diagnosis was considered as: 
‘confirmed’ when the diagnosis was confirmed with a 
cytogenetic or molecular method or when other criteria 
were considered sufficient to support the diagnostic con-
firmation and no additional investigations were deemed 
necessary; ‘likely’ if the diagnostic hypothesis was likely 
given the available data, but not all the signs or tests nec-
essary to confirm the diagnosis were available; ‘ongoing’ 
when the diagnosis was in progress and no examination 
results had yet come back for this diagnosis; ‘indetermi-
nate’ when the physician could not give an opinion on the 
diagnosis in the absence or unavailability of diagnostic 
tests, or due to non-contributory tests. When patients did 
not have a diagnosis (‘unlabeled’), they could be classified 
according to a diagnostic category, such as developmen-
tal disorder with ID, non-syndromic ID, developmental 
disorder without ID, malformative syndrome with short 
stature, syndromic epilepsy. Also, to annotate the diagno-
sis, the database provided keywords based on the London 
Dysmorphology Database that was enriched with entities 
from the “Collège Français d’Echographie Foetale” the-
saurus for fetuses.
Data curation has been described in previous publica-
tions [9, 10]. The principle lies in controls at recording 
and regular data management. Since an RCRD/CERD 
cannot access the data of other RCRD/CERD, if an indi-
vidual patient was seen in different centers, a new record 
was created, leading to duplicates. Records from the same 
patients but generated by different centers were mapped 
together using Registry Plus Linkplus [11] for the whole 
cohort.
Half of the accounts in the database were created for 
administrative staff, a quarter for non-medical non-
administrative staff, and another quarter for medical 
staff. The task of creating a new file or updating activity 
was mainly done by a medical staff. Administrative staff 
mainly had access for activity reports, patient searches, 
and updating patient data.
Focus on specific diseases and chromosomal anomalies
A focus on certain diseases was decided to show 
the potential information that can be obtained from 
CEMARA. Sub-cohorts were created for two mono-
genic diseases (Rubinstein Taybi and Cornelia de Lange 
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syndromes) and two chromosomal disorders (Williams 
and 22q11 microdeletion syndromes). We chose these 4 
conditions because they are emblematic diseases in the 
network, and they are commonly taken as examples to 
represent developmental diseases because they have been 
described for a very long time, are generally clinically 
recognizable, and are known by practitioners.
The sub-cohort of patients with chromosomal anom-
alies was also considered. For the latter sub-cohort, 
anomalies were described through chromosomal anom-
aly descriptor according to seven subtypes of anomalies 
(balanced, structural/unbalanced, autosome numerical, 
allosome numerical, breakage, fragile site, uniparental 
disomy) along with the chromosome/arm affected and 
the presence of mosaicism. For example, 14 subtypes 
were available for an unbalanced anomaly: four relating 
to chromosomal markers and six to duplication/deletion. 
The remaining referred to isochromosome, partial tetras-
omy/triplication, ring chromosome, and an open subtype 
if none of the above applied. A few frequent anomalies 
had a specific code (e.g. PWS for Prader-Willi syndrome) 
but were still considered within the descriptor.
Statistical method
All MDS mandatory items and chromosomal anomalies 
were described using frequencies for categorical data; 
and means ± SD or medians and interquartile range 
(IQR) for continuous variables according to their distri-
bution. Some optional MDS items were only described 
in the subgroup analysis because only relevant in this 
context, such as birth parameters which are only rel-
evant for certain diagnoses. The proportion of patients 
Fig. 1 Demographic information, Care pathways. A Number of patient visits from 2007 to 2017, comprising affected individuals (red) and 
non‑affected relatives (blue). B Age and related sex distribution of affected/unaffected individuals. The median age in affected individuals was 
11 years, and the median age in non‑affected individuals was 37 years. Within the affected population, 51.6% (n = 86,304) of the affected patients 
were males and 44.4% females (n = 74,319). C Objectives of activity. 55% (n = 208,433) of activities were for diagnosis purposes, 31% (n = 118,244) 
for genetic counseling, and only 36% (n = 136,286) for follow‑up (FU) care, 9.7% (n = 37,397) for prenatal diagnosis, and 0.3% (n = 999) for 
emergency, taking into account that the same patient can be seen for more than one reason. D Patient referral. Patients are mainly referred to a 
RCRD/CERD by a pediatrician when the index case is a child (n = 55,755; 46%), and by a specialist when the affected patient is an adult (n = 14,053; 
34%). For Children: Self: 4% (n = 5242); Patient Support Group: 0% (n = 373); General Practitioner: 2% (n = 2399); Pediatrician: 46% (n = 55,755); 
Other Specialist: 17% (n = 20,555); Geneticist: 3% (n = 3372); Gynecologist‑Obstetrician: 12% (n = 14,778); Centre of maternal and child health: 
0% (n = 340); Support center: 6% (n = 7345); Multi‑disciplinary diagnosis center: 7% (n = 8599); Prenatal screening centre: 0% (n = 163); Other: 
1% (n = 1322); Unknown: 1% (n = 893). For Adults: Self: 16% (n = 6452); Patient Support Group: 1% (n = 324); General Practitioner: 7% (n = 3073); 
Pediatrician: 17% (n = 7050); Other Specialist: 34% (n = 14,053); Geneticist: 6% (n = 2495); Gynecologist‑Obstetrician: 11% (n = 4434); Centre of 
maternal and child health: 0% (n = 51); Support center: 3% (n = 1219); Multi‑disciplinary diagnosis center: 2% (n = 713); Prenatal screening centre: 
0% (n = 11); Other: 3% (n = 1186); Unknown: 1% (n = 503)
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with developmental disorder in each French department 
was estimated as the ratio between patients seen in the 
RCRD/CERD for one of the targeted diseases and living 
in the geographic area (called “patients”) and the mean 
population living in the region during the study period 
according to the National Institute of Statistics and Eco-
nomic Studies (INSEE) census (2017). The great-circle 
distance was used to measure distance between the resi-
dence and the place where the patients accessed care. The 
statistical software was R for Windows, version 3.5.1.
Results
Demographic information from the database
Over 10  years, data was collected for 228,243 individu-
als. The data included 167,361 affected patients and 
60,882 unaffected patients. Unaffected patients were 
either healthy carriers or the relatives of an index patient, 
most often the parents of an affected child. The database 
includes vital status, and 4.8% of affected patients were 
reported as deceased.
The median age in affected individuals was 11  years, 
and the median age in non-affected individuals was 
37 years. Within the affected population, 86,304 (51.6%) 
of patients were males and 74,319 (44.4%) were females 
(4% undetermined). Results are shown in Table  1. Fig-
ure 1A shows the number of patients having completed 
an activity record each year. The age and related sex dis-
tribution is shown in Fig. 1B.
Care pathway
A vast majority of patients were only seen once per year 
(82, 9%; n = 189,213), 16.5% were seen 2–3 times a year 
(n = 37,661), and only 0.6% more than 3 times (n = 1,369). 
The objectives of activity were distributed as follows: 55% 
were for diagnosis, 31% for genetic counseling, 36% for 
follow-up/care, 9.7% for prenatal diagnosis, and 0.3% 
for emergency. It should be noted that a patient can be 
seen for more than one reason (Fig.  1C). Regarding the 
type of visit, 85% of visits occurred on an outpatient basis 
(n = 310,306) and 14% were for expert medical advice 
for a patient hospitalized in another department or from 
a patient file (n = 40,601). Patients were mainly referred 
to a RCRD/CERD by a pediatrician when the index case 
was a child (46%) and by a specialist when the affected 
patient was an adult (34%) (Fig. 1D). 16% of adults were 
self-referred.
The distance to the closest expert consultation is shown 
in Additional file 2: Figure S1C. A median of 25.1 km was 
found (IQR = 6.3 km–64.2 km).
Analysis of diagnoses
Among the 2,872 diagnoses in this cohort, most diseases 
were found in 0–10 patients (66.5%, n = 1,907), showing 
the frequency of ultra-RD among developmental disor-
ders. 28% (n = 802) were found in 10–100 patients, 5.2% 
(n = 149) in 100–1,000 patients, and 0.4% (n = 11) in 
1,000–10,000 patients (Fig.  2A). The 20 most frequent 
diseases are shown in Table  2, and the most frequent 
diagnostic categories are shown in Additional file  1: 
Table S2, with the proportion of patients seen within the 
AnDDI-Rares network versus the entire CEMARA net-
work. Symptoms were noted prior to birth or within the 
first year of life in 67.3% (n = 84,772) of cases (Fig.  2B). 
Nearly half of patients had received no diagnosis (45.6%; 
n = 74,632), and the diagnostic status was unlabeled for 
6.7% of patients (n = 10,923) (Table  1). When diagnosis 
was provided, 32% (n = 52,271) were at a disease level in 
Orphanet and 19.7% (n = 32,260) were in diagnostic cat-
egories. Inheritance was autosomal dominant in 25% of 
cases, autosomal recessive in 11% of cases, chromosomal 
in 10% of cases, X-linked in 6% of cases, suspected mul-
tifactorial in 1.3% of cases, and mitochondrial in 0.4% 
of cases (Fig.  2D). Inheritance was unknown in 46% 
(n = 34,305) of declared cases.
Sub‑cohorts analysis
The registry also allows for a more focused approach 
since it is possible to identify specific diseases such as 
Cornelia de Lange syndrome, Rubinstein syndrome, 
22q11 microdeletion, and Williams’ syndrome. A man-
ual review of double entries was conducted for these 
4 sub-cohorts, on top of the previously described data 
curation procedures, using birthdate, sex, first name 
and last name. The process and results are shown in 
the Additional file 3: Data 1. We provide the number of 
patients with these four diseases found in CEMARA in 
Table 3, in order to provide a comparison with the big-
gest cohorts available in the literature. Within each dis-
ease, birth measurements and pregnancy length seemed 
to be consistent. Since most births occurred at term, 
birth measurements were congruent with the general 
population (Fig. 3A). Most patients were under 18 years 
old at their last visit, with a predominance between 5 
and 15  years old (Fig.  3B). In the proportion of antena-
tal expression in the age at first signs, we can clearly see 
the effects of Cornelia de Lange syndrome in Fig. 3C. Fig-
ure  3D shows the patient age at diagnosis. The registry 
also provides the opportunity for short and long term 
outcome analysis. Among the 261 patients with Rubin-
stein-Taybi syndrome, one patient died at 27 days. Two of 
the 232 patients with Cornelia de Lange syndrome died 
at delivery or within hours, and two others died older 
than 2-year-old. Two patients among the 648 patients 
with Williams syndrome died before the age of 2, a third 
one died at 26  months. Among the 1911 patients with 
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Table 1 Description of the population
Number of patients in the cohort 228,243
Number of affected patients in the cohort 167,361
Median age at endpoint (in years)
 Affected 11 (Q1 = 5; Q3 = 21)
 Unaffected 37 (Q1 = 30; Q3 = 43)
Male to female sex ratio 1.16
Reported death for affected patients 4.8%
Residence (Region)
 Auvergne Rhône Alpes 17,976
 Bourgogne Franche Comte 7,670
 Bretagne 13,701
 Centre Val De Loire 5,094
 Corse 562
 Départements D’Outre‑Mer 4,733
 Grand‑Est 15,179
 Hauts De France 23,172
 Ile De France 22,362
 Normandie 2,425
 Nouvelle Aquitaine 11,416
 Occitanie 10,150
 Pays De La Loire 12,899
 Provence Alpes Côte D’Azur 13,139
Objective of visit (N = 381,209)
 Diagnosis 55%
 Genetic counseling 31%
 Follow‑up/care 36%









Transmission mode (N = 73,911)
 Autosomal dominant 18,710
 Autosomal recessive 7,911
 Chromosomal 7,284
 X‑linked 4,477




Affected patients were referred by (%)
 Self 4% 16%
 Patient Support Group 0% 1%
 General Practitioner 2% 7%
 Pediatrician 46% 17%
 Other Specialist 17% 34%
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microdeletion 22q11.2, 17 patients died before the age of 
2, 7 between 2 and 18 years, and 4 died later in life.
Additional file  1: Figure S1C shows the distance trav-
elled by the families to go to a reference center for their 
disease. For example, patients with Rubinstein-Taybi syn-
drome often travel to Bordeaux, which is home to the 
expert center for this disease.
The CEMARA registry includes 34,737 patients car-
rying chromosomal anomalies, among which 22,019 are 
part of the AnDDI-Rares network. Figure 4A shows the 
repartition of chromosomal anomalies and especially 
for unbalanced anomalies (Fig.  4B). Figure  4C showed 
the frequency at which each chromosome is implicated. 
Chromosomal anomalies were more frequent for all 
Table 1 (continued)
Children Adults
 Geneticist 3% 6%
 Gynecologist‑Obstetrician 12% 11%
 Centre of maternal and child health 0% 0%
 Support center 6% 3%
 Multidisciplinary diagnosis centre 7% 2%
 Prenatal screening centre 0% 0%
 Other 1% 3%
 Unknown 1% 1%
Fig. 2 Frequency of diseases / diagnosis. A Range of patient numbers within the 2,872 diseases part of the AnDDI‑Rares spectrum. The majority 
of diseases were found in 0–10 patients (66.5%, n = 1,907). 28% (n = 802) were found in 10–100 patients, 5.2% (n = 149) in 100–1,000 patients, 
and 0.4% (n = 11) in 1,000–10,000 patients. B Age range at first signs (n = 125,842). The median age at first signs is at birth (IQR = 2.5 years). The 
beginning of symptoms was noted within the first year of life in 67.3% of cases (n = 84,772). C Diagnostic status within the network. A confirmed 
diagnosis was found in 34% of cases (n = 56,515), undetermined in 27% (n = 10,923), ongoing in 19% of cases (n = 30,465), probable in 11% 
(n = 17,651), non‑classifiable in 7% (n = 3,669) of patients, non‑available in 2% (n = 3,669). D Mode of inheritance of diseases within the network. 
The mode of inheritance was undetermined in 46% of cases (n = 34,305), autosomal dominant in 25% of cases (n = 18,710), autosomal recessive 
in 11% of cases (n = 7,911), chromosomal in 10% of cases (n = 7,284), X‑linked in 6% of cases (n = 4,477), suspected multifactorial in 1.3% of cases 
(n = 956), and mitochondrial in 0.4% of cases (n = 268). This information was optional
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acrocentric chromosomes as compared to non-acrocen-
tric chromosomes. The most frequently affected chro-
mosomes were 21 (8.6%), 15 (6.7%), and 22 (6.7%). It was 
then possible to focus on each chromosome. Figure  5 
represents the distribution of chromosomal anomalies 
for the 3 most frequent chromosomes implicated, but 
Table 2 The twenty most frequent diseases, with their ORPHA code, number seen in the AnDDI‑Rares network, number in CEMARA 
(differential number seen by reference centers of other networks)
Orpha_Code Disease Number of patients 
in the_AnDDI‑Rares 
network
Total number of 
patients in the CEMARA 
database










870 Trisomy 21 3512 4459 94 4 0 (6)
636 Neurofibromatosis type 1 2943 5673 68 23 36 (113)
558 Marfan Syndrome 2848 3487 33 38 180 (288)
567 22q11.2 microdélé‑
tion syndrome
2009 2592 87 6 7 (72)
908 Fragile X syndrome 1580 2339 85 5 132 (330)
648 Noonan syndrome 1374 1703 61 26 24 (128)
98249 Ehlers‑Danlos syndrome 1120 1980 22 62 216 (300)
805 Tuberous sclerosis 1046 1813 69 22 12 (138)
881 Turner syndrome 993 3923 92 4 ‑6 (102)
666 Osteogenesis imperfeceta 766 2487 53 32 0 (36)
484 Klinefelter syndrome 762 1450 96 1 0 (246)
273 Myotonic dystrophy 
type 1
682 4910 84 9 276 (372)
904 Williams syndrome 681 907 86 8 21 (42)
116 Beckwith‑Wiedemann 
syndrome
639 1090 62 23 0 (7)
3380 Trisomy18 554 618 93 4 − 6 (0)
1991 Labial cleft with or with‑
out palatine cleft
510 2374 74 14 − 6 (6)
718 Isolated Pierre Robin syn‑
drome
412 1799 52 26 0 (0)
1906 Valproate embryofoe‑
topathie
408 458 23 72 72 (128)
83330 Spinal muscular atro‑
phy type 1
408 1438 82 5 276 (377)
374 Goldenhar syndrome 405 773 32 49 0 (6.5)
Table 3 Number of patients in CEMARA for 4 diseases taken as examples (Microdeletion 22q11.2, Williams Syndrome, Cornelia de 
Lange Syndrome, Rubinstein‑Taybi Syndrome), and comparison with the largest cohorts published to date
CEMARA Largest cohorts in the 
literature






% of confirmed 
diagnosis in AnDDI‑
Rares






1911 2592 87 88 1393 Homans et al. [20]
904 Williams Syndrome 648 907 85 86 106 Lugo et al. [21]
199 Cornelia de Lange 
Syndrome
232 360 50 52 486 Mehta et al. [22]
783 Rubinstein‑Taybi 
Syndrome
261 373 73 73 93 Schorry et al. [23]
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also chromosome 1 as an example of non-acrocentric 
chromosome. In chromosome 1, reciprocal translocation 
was the most frequent chromosomal anomaly, followed 
by proximal and distal deletions. For chromosome 15 and 
22, proximal deletions or duplications were the most fre-
quent chromosomal anomalies. For chromosome 21, the 
trisomy of the whole chromosome was the most frequent 
chromosomal anomaly.
Discussion
We present here the organization of the registry for rare 
developmental disorders, including intellectual disabil-
ity or not as part of the AnDDI-Rares network, and pro-
vide an analysis of what we have learned from the first 
10 years using the CEMARA database.
Information and knowledge about RD is usually the 
result of data collection and registries implemented 
with academic and/or commercial interests and with 
a limited scope. Interestingly, the online rare disease 
database Orphanet [12] indexes a total of more than 
700 registries and databases on RD involving European 
research, and it can thus be used to estimate disease 
prevalence [13]. These registries and databases have a 
variety of aims and differ in their organization, quality 
and database structure, usually monitoring one dis-
ease or a group of related diseases [14–16]. In order 
to encourage the development of knowledge about 
RD, several countries have launched national initia-
tives to build registries including all RDs and with the 
suggestion of international cooperation, in particular 
within the European Reference Networks [17]. These 
registries, if properly implemented with accurate and 
high-quality clinical data and long-term support, can 
facilitate health service planning, epidemiological 
research and clinical trial recruitment. Nevertheless, 
the collected data must be congruent with the aims of 
Fig. 3 Focus on two chromosomal diseases (Williams (n = 681) and 22q11 microdeletion (n = 2,008) syndromes) and two monogenic diseases 
(Rubinstein‑Taybi syndrome (n = 290) and Cornelia de Lange syndrome (n = 246)) as examples. A Birth measurements and term at birth. For each 
measurement by disease, number of patients. Cornelia de Lange syndrome: birth height (n = 99), birth weight (n = 110), head circumference 
(n = 97), term at birth (n = 252). 22q11 microdeletion syndrome: birth height (n = 764), birth weight (n = 862), head circumference (n = 710), term 
at birth (n = 2,033). Rubinstein Taybi syndrome: birth height (n = 171), birth weight (n = 184), head circumference (n = 150), term at birth (n = 295). 
Williams syndrome: birth height (n = 317), birth weight (n = 352), head circumference (n = 291), term at birth (n = 680). B Patient’s age at last 
visit. For each disease, number of patients: Cornelia de Lange syndrome (n = 246), 22q11 microdeletion syndrome (n = 1,998), Rubinstein‑Taybi 
syndrome (n = 288), Williams syndrome (n = 680). C Patient’s age at first symptoms. For each disease, number of patients: Cornelia de Lange 
syndrome (n = 222), 22q11 microdeletion syndrome (n = 1,701), Rubinstein‑Taybi syndrome (n = 256), Williams syndrome (n = 574). D Patients’ 
age at diagnosis. For each disease, number of patients: Cornelia de Lange syndrome (n = 123), 22q11 microdeletion syndrome (n = 1,251), 
Rubinstein‑Taybi syndrome (n = 165), Williams syndrome (n = 395). On all graphs, Williams syndrome is represented in purple, 22q11 microdeletion 
syndrome in green, Rubinstein‑Taybi syndrome in blue and Cornelia de Lange syndrome in red
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the registry. Registries are particularly important for 
rare or poorly-understood diseases that affect small 
numbers of patients, complex delayed diagnoses, a pro-
pensity for variable standards of care and limited treat-
ment options.
The first French RD initiative, CEMARA, has been 
collecting information on RD epidemiology and related 
medical activities from RCRD and CERD on a national-
level since 2007. To date, the data entered in CEMARA 
has already been used by some networks for RD [18]. 
Other publications have also been facilitated by 
CEMARA’s infrastructure [19]. More specifically, data 
on age, sex ratio, type of care, median distances trav-
elled by patients, the most frequent type of referrals, 
and diagnosis categories or precise diagnoses (when 
available) can be obtained.
Interestingly, when compared with the data obtained 
for the Head and Neck Network, in which nearly 80% 
of patients are required to visit Paris hospitals to 
obtain diagnosis, care or follow up [18], the distribu-
tion of RCRD/CERD within the AnDDI-Rares network 
(Additional file  2: Figure S1A) has optimized the dis-
tance patients must travel to obtain specialist care for 
RD.
Unlike most registries collecting detailed information 
on specific rare diseases, the main aim of this nationwide 
database is not to improve knowledge on the natural his-
tory of diseases. This is because the scope of CEMARA 
covers all rare diseases, which is too vast to achieve such 
a goal. Even so, some aspects of a disease’s natural history 
can be analyzed straightforwardly (age at first signs, age 
at death, e.g.) while others can be inferred (based on the 
care pathway, age at diagnosis, e.g.). A deep phenotypic 
description is possible through HPO terminology, but 
we observed that not all physicians extensively code this 
optional information.
In addition, we demonstrated the information that can 
collected on specific topics using the examples of four 
well-known easily recognizable diseases, including two 
chromosomal abnormalities (22q11 microdeletion and 
Williams syndromes) and two mendelian diseases (Cor-
nelia de Lange (CdLS) and Rubinstein-Taybi syndromes 
Fig. 4 Focus on chromosomal anomalies. A Chromosomal anomalies described (n = 11,950). The unbalanced structural anomalies are mostly 
described (59.4%, n = 7103) whereas number anomalies only represent 18.8% (n = 2247). B Unbalanced chromosomal anomalies described 
(n = 7,103). Distal deletion: 22.6% (n = 1603); proximal deletion: 34.9% (n = 2480); distal duplication: 10.2% (n = 724); proximal duplication 
17.1% (n = 1218); duplication and deletion (only one chromosome): 3.3% (n = 234); proximal duplication (inserted elsewhere): 0.6% (n = 46); 
isochromosome: 1.4% (n = 98); Marker: 2.4% (n = 167); Missing data: 2.6% (n = 187); Other: 1.7% (n = 119); ring chromosome: 1.6%(n = 114); partial 
triplication/tetrasomy: 1.6% (n = 113).C Frequency of implication of each chromosome (n = 12,614). Chromosomal anomalies are more frequent 
for all acrocentric chromosomes as compared to non‑acrocentric chromosomes, the more represented being chromosome 21 (n = 1,086; 8.6%), 
chromosome 15 (n = 856; 6.7%), and chromosome 22 (n = 849; 6.7%)
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(RTS)). In these examples, the large number of patients in 
the database makes it possible to compare with other ini-
tiatives [20–23]. CEMARA collects a greater number of 
patients compared with the the biggest available national 
cohort for three of the four diseases chosen herein. Only 
the Children’s Hospital of Philadephia’s Cohort on Cor-
nelia de Lange was bigger than CEMARA’s.
In the field of RD, patient organizations are usually 
the best resource for reaching out to a significant num-
ber of patients for a given disease. However, this national 
database proves to be an even more efficient tool to col-
lect patient data since it includes information on every 
patient seen in an RCRD and some CERD. It can thus 
provide larger cohorts than those currently found in the 
literature for most RD. Similarly, over time the data-
base has accumulated a vast number of patients with 
the various chromosomal abnormalities, diagnosed by 
karyotype, FISH or array-CGH. Data on chromosomal 
abnormalities associated with developmental pheno-
types can be of great interest, yet there are no extensive 
epidemiological references in the literature since the use 
of chromosomal microarrays became more common. 
Researchers can now solicit the network if they want to 
focus on a certain disease and contact the referring clini-
cians all over the country for additional information. This 
possibility will be interesting for international collabora-
tions on the increasing numbers of ultra-RD, but also for 
long-term follow-up of well-known diseases.
The CEMARA registry is comparable with other 
national projects that have been published in the lit-
erature. In Europe, CEMARA resembles most its Italian 
counterpart, which launched in 2001 as a government 
baseline project to support health policy decision-mak-
ing in the field of RD [24, 25]. They established a national 
registry of RD as a network of regional networks through 
247 formally designated centers with recognized exper-
tise, reaching full coverage of the country by 2011. After 
a common data set was defined for the country, they 
performed different quality control processes at regional 
and national levels. One of the main issues was track-
ing duplicate records. Up to June 2012, they recorded 
110,841 patients. Data was carefully monitored through a 
validation process using formal criteria, and issues in the 
data were corrected by the data sources. Data of age at 
onset and sex distribution were provided for about 400 
diseases, and incidence and/or birth prevalence provided 
Fig. 5 Distribution of chromosomal anomaly for the 3 most frequent chromosomes implicated, as well as chromosome 1, as an example of 
non‑acrocentric chromosome. For these graphs, "del dist": distal deletion; "del prox": proximal deletion; "dup dist": distal duplication; "dup prox": 
proximal duplication on the same chromosome; "dup + del": duplication and deletion (only one chromosome); "dup + ins": proximal duplication 
(inserted elsewhere); "invpara": paracentric inversion; "invperi": pericentric inversion; "iso": isochromosome; "mar": Marker; "mat": maternal; 
"mono": monosomy; "pat": paternal;"ploid": triploidy/tetraploidy; "rec": reciprocal translocation; "ring": ring chromosome; "rob": robertsonian 
translocation; "tri": trisomy; "trip": partial triplication/tetrasomy; "Other": other anomalies. A Chromosome 1, reciprocal translocation was the most 
frequent chromosomal anomaly, followed by proximal and distal deletions. B Chromosome 15, proximal deletions or duplications were the most 
frequent chromosomal anomalies. C Chromosome 21, the trisomy of the whole chromosome was the most frequent chromosomal anomaly. D 
Chromosome 22, proximal deletions or duplications were the most frequent chromosomal anomalies
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for 275 diseases and 47 disease groups, which, altogether, 
comprise a substantial part of the known RD. The main 
difference lay in the fact that CEMARA was launched as 
a national project, allowing a nation-wide common data 
collection from the outset, thus a greater hindsight, com-
pared with the Italian project. Both projects shared simi-
larities regarding the type of data which may foreshadow 
comparative and/or pooling data studies.
Other initiatives exist outside of Europe. In the major-
ity of cases, the strategy was to create alliances of exist-
ing RD registries, with the creation of a central repository 
aiming to improve consistency, harmonize data, sup-
port the development of knowledge on RD, share data, 
enhance research collaboration, improve interoperability, 
and reduce costs. The USA National Institute of Health 
launched a movement to create a Global RD Patient 
Registry and Data Repository in 2010 [26], but unlike 
CEMARA the contribution to this RD-hub was based on 
goodwill. In China, a nationwide RD registry has been 
set up along with a bio-bank of genomic data to pro-
vide standardization and create research collaborations, 
both domestic and international [27, 28]. In 2017, Japan 
decided to combine data from 300 RD projects through 
a cross-sectional data integration platform (RADDAR-J) 
[29], aiming to promote data sharing and secondary use 
for research and collaboration. This Japanese initiative 
only focused on 300 RD, thus lacked information com-
pared to CEMARA. A global observatory for rare disease 
could be achieved through the combination of these vari-
ous initiatives, to the great benefit of patients: given the 
small number of cases in each country, it is of paramount 
importance that data be analyzed on the widest possible 
scope.
This work provides elements relative to the function-
ing of the database over the first 10 years. We have iden-
tified many important limitations that we wish to share 
with other countries which are attempting to implement 
nationwide epidemiological projects. Epidemiological 
information regarding RD is challenging to collect for a 
number of reasons, including the coding and classifica-
tion of RD. In our case, this difficulty was overcome with 
the implementation of a unique disease identifier result-
ing from the exhaustive work of the online rare disease 
database Orphanet on the labeling of diseases: OrphaCo-
des. While exhaustiveness is usually is a challenge for 
any registry, public funding conditional to participation 
in the CEMARA project will remain a significant incen-
tive. Unfortunately, such an incentive is not in place for 
CERD, even if the French Ministry of Health is provid-
ing other operational support in order to facilitate inclu-
sion. Indeed, the RCRD have an obligation to enter all of 
their activity into the CEMARA database to keep their 
funding, unlike the CERD. As a result, most CERD do 
not collect patient data, so there are limits to the epide-
miological work that can be carried out. Another minor 
limitation is that of duplicates: patients can consult in dif-
ferent RCRD/CERD, which implies the creation of a new 
file, and so any multicenter analysis requires the identifi-
cation of potential duplicates. Another limit is a lack of 
homogeneity in the way data are entered in the differ-
ent RCRD/CERD since the definition of items may not 
always be straightforward. For instance, a physician may 
consider a diagnosis as confirmed based on clinical evi-
dence, while another may consider that confirmation is 
achieved only after genetic confirmation. Some improve-
ments have been made to overcome these issues, includ-
ing a frame of reference to homogenize the way data is 
entered, and communication in meetings to insist on the 
importance of epidemiology in France. A major issue is 
the surveillance of patients with no diagnosis, which is 
considered a priority of the third national RD plan [30]. 
Indeed, the database does not permit to identify age at 
clinical diagnosis, age at diagnosis of a category, or a pre-
cise clinical diagnosis by a chromosomal/molecular con-
firmation. This issue will be improved in the next version 
of the database, since it is part of the vast epidemiological 
national surveillance project for undiagnosed patients. It 
is also difficult to ensure that the data are updated when 
a diagnosis is made, particularly when the results are not 
delivered in the context of a novel referral to the RCRD/
CERD. Despite the limited amount of information col-
lected, specific studies could be performed within the 
network through the identification of the exact number 
of patients by RCRD/CERD in France with a disease of 
interest. This would enable national studies to be per-
formed, or, through linkage with other sources, to seek 
data that could be used to improve the management of 
RD, facilitate research, such as phenotype/genotype cor-
relations or drug surveillance, or exposes economic issues 
such as the burden of RD. New perspectives are currently 
raising with the launch of a registry of patients with no 
diagnosis, enabling to better identify patients without 
diagnosis, to whom new research programs could be 
proposed. Also, at the dawn of the arrival of therapeu-
tic projects in RD, the database will allow the selection 
of potential candidates for a therapeutic trial according 
to their demographic characteristics. For this purpose, 
although individual sites cannot access data from other 
sites, it is possible to ask the project coordination team, 
in agreement with the network, for the number of people 
affected by selected criteria and their referring center. In 
this way, the applicant can contact his or her colleagues 
in the framework of his project.
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Conclusions
Thanks to the national epidemiological project 
launched by the French Ministry of Health 10 years ago, 
the main characteristics of French patients with RD are 
available, potentially leading to the identification of 
patients for specific studies. Issues with exhaustiveness 
shall be progressively resolved thanks to continuous 
human and financial support, and coding methods are 
continuously improved through harmonization work. 
AnDDI-Rares’ experience with CEMARA will ben-
efit other French rare disease networks since they are 
all joining the French National Rare Disease Registry, 
a registry integrating all CEMARA data that is to be 
deployed more broadly throughout the national net-
work of expert centers. New perspectives are also being 
developed with the expansion of MDS data collection 
to all rare disease networks in France and Europe.
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